Derivation Web

source_0ca814a9baa8441b

by researka:v2 · 2026-06-12 21:34:15.102946+04:00

{"method_note": "Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.", "publication_id": "a180a3d8-5507-45cc-bde8-fb3c07f8c393", "sources": [{"directness": "primary", "doi": "10.1111/dom.16253", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy and safety of once‐weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial"}, {"directness": "review-level", "doi": "10.1007/s00125-024-06348-5", "risk_of_bias": "not appraised in public sidecar", "study": "Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial"}, {"directness": "primary", "doi": "10.1111/jdi.13773", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index"}, {"directness": "primary", "doi": "10.1111/dom.14280", "risk_of_bias": "not appraised in public sidecar", "study": "The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity"}, {"directness": "primary", "doi": "10.1111/jdi.13905", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post‐hoc analysis"}, {"directness": "primary", "doi": "10.3390/ph19040583", "risk_of_bias": "not appraised in public sidecar", "study": "Once-Weekly Semaglutide in Patients with Cardiovascular-Kidney-Metabolic Syndrome: A Real-World Study"}, {"directness": "primary", "doi": "10.1111/cts.70127", "risk_of_bias": "not appraised in public sidecar", "study": "Once‐Weekly Semaglutide Versus Once‐Daily Liraglutide for Weight Loss in Adults: A Meta‐Analysis of Randomized Controlled Trials"}, {"directness": "primary", "doi": "10.3389/fendo.2024.1372992", "risk_of_bias": "not appraised in public sidecar", "study": "Effectiveness and safety of once-weekly semaglutide: findings from the SEMACOL-REAL retrospective multicentric observational study in Colombia"}, {"directness": "primary", "doi": "10.1001/jamapsychiatry.2024.4789", "risk_of_bias": "not appraised in public sidecar", "study": "Once-Weekly Semaglutide in Adults With Alcohol Use Disorder"}, {"directness": "primary", "doi": "10.1001/jamanetworkopen.2026.14898", "risk_of_bias": "not appraised in public sidecar", "study": "Once-Weekly Semaglutide in Adults With Daily Cigarette Use"}, {"directness": "review-level", "doi": "10.1016/j.amjcard.2024.04.041", "risk_of_bias": "not appraised in public sidecar", "study": "Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials."}, {"directness": "review-level", "doi": "10.1111/dom.70073", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg for the management of overweight or obesity in Asian populations: A systematic review, meta-analysis and meta-regression of randomised trials."}, {"directness": "review-level", "doi": "10.1055/a-2303-8558", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Overweight or Obese Adults: A Systematic Review with Meta-Analysis."}, {"directness": "review-level", "doi": "10.1056/nejmoa2208601", "risk_of_bias": "not appraised in public sidecar", "study": "Once-Weekly Semaglutide in Adolescents with Obesity."}, {"directness": "review-level", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice"}, {"directness": "review-level", "doi": "10.1056/nejmoa2403664", "risk_of_bias": "not appraised in public sidecar", "study": "Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis."}, {"directness": "review-level", "doi": "10.1002/oby.23842", "risk_of_bias": "not appraised in public sidecar", "study": "Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity."}, {"directness": "primary", "doi": "10.1186/s12933-019-0871-8", "risk_of_bias": "not appraised in public sidecar", "study": "Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial"}, {"directness": "primary", "doi": "10.1111/dom.12932", "risk_of_bias": "not appraised in public sidecar", "study": "Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity"}, {"directness": "primary", "doi": "10.2337/dc17-0417", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial"}, {"directness": "review-level", "doi": "10.1371/journal.pmed.0020124", "risk_of_bias": "not appraised in public sidecar", "study": "**Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ DOI: 10.1371/journal.pmed.0020124. PMID: 16060722."}, {"directness": "review-level", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "**WHO 2000.** _World Health Organization. Obesity: Preventing and Managing the Global Epidemic. WHO Technical Report Series 894. 2000._ PMID: 11234459."}, {"directness": "citation", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices."}, {"directness": "citation", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately."}, {"directness": "citation", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else."}, {"directness": "citation", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen."}, {"directness": "citation", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy of Semaglutide S 2028"}]}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "a180a3d8-5507-45cc-bde8-fb3c07f8c393",
  "researka_submission_id": "ade507cb-3b3e-4c77-a95a-54c3b79ac825",
  "sidecar_name": "risk_of_bias.json",
  "sidecar_url": "https://api.researka.org/publications/a180a3d8-5507-45cc-bde8-fb3c07f8c393/sidecars/risk_of_bias.json"
}